Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab trough levels and side effects in IBD remission
NL-OMON40963Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of adalimumab in inflammatory bowel disease (IBD), Crohn's disease and autoimmune colitis, sponsored by Amsterdam University Medical Center. Primary endpoint: Serum adalimumab trough level concentration. Started Aug 2014; status: active, not recruiting.
02
Drugs
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on NL-OMON40963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40963.